1309774-03-5

Basic information

• Product Name: 7-BroMo-2-chloro-1,5-naphthyridine
• Synonyms: 7-BroMo-2-chloro-1,5-naphthyridine
• CAS NO: 1309774-03-5
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.48776
• Mol File: 1309774-03-5.mol

Chemical Properties

• Boiling Point: 319.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.762±0.06 g/cm3(Predicted)
• PKA: -0?+-.0.10(Predicted)
• CAS DataBase Reference: 7-BroMo-2-chloro-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMo-2-chloro-1,5-naphthyridine(1309774-03-5)
• EPA Substance Registry System: 7-BroMo-2-chloro-1,5-naphthyridine(1309774-03-5)

Safety Data

• Hazardous Substances Data: 1309774-03-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Organic Synthesis:
7-bromo-2-chloro-1,5-naphthyridine is utilized as a building block for the development of new pharmaceutical compounds, leveraging its unique structural features and potential biological activity. Its presence in the synthesis process can contribute to the creation of novel therapeutic agents.
Used as a Reagent in Chemical Reactions:
7-bromo-2-chloro-1,5-naphthyridine also serves as a reagent in various chemical reactions, facilitating the synthesis of other complex organic molecules. Its reactivity and stability make it a useful component in the preparation of diverse chemical products.
Used in the Manufacture of Other Compounds:
7-bromo-2-chloro-1,5-naphthyridine is employed as a precursor in the production of additional compounds, expanding its applications across different chemical and pharmaceutical industries.
Safety and Handling:
Due to its potential hazards, 7-bromo-2-chloro-1,5-naphthyridine is stored and handled following standard chemical safety procedures to ensure the safety of personnel and the environment.

Upstream product

• 17965-71-8 3-bromo-1,5-naphthyridine 
• 56247-24-6 3-bromo-1,5-naphthyridine-5-oxide 
• 6298-19-7 2-chloro-3-aminopyridine 
• 10261-82-2 1,5-naphthyridin-2(1H)-one 
• 7689-62-5 2-chloro-1,5-naphthyridine 
• 13535-01-8 3-amino-5-bromopyridine 
• 10261-82-2 2-Hydroxy-1,5-naphthyridin 
• 27305-48-2 1,5-naphthyridine N-⁽¹⁾-oxide 
• 39620-02-5 5-bromonicotinoyl chloride 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 28733-43-9 5-bromonicotinamide 
• 959616-36-5 7-bromo-1,2-dihydro-1,5-naphthyridin-2-one 
• 254-79-5 1,5-naphthyridine 

Downstream Products

• 1309773-60-1 1-tert-butyl-3-[7-(4-hydroxy-3-methoxyphenyl)-1,5-naphthyridin-2-yl]urea 
• 1309774-11-5 N₇-(3,4,5-trimethoxy-phenyl)-[1,5]naphthyridine-2,7-diamine 
• 1309773-66-7 1-ethyl-3-[7-(3,4,5-trimethoxy-phenylamino)-[1,5]naphthyridin-2-yl]-thiourea 
• 1422123-35-0 C₂₁H₂₂N₄O₃ 
• 1422123-99-6 C₂₂H₂₂N₆O 
• 1422124-32-0 C₂₁H₂₀N₆O 
• 1422124-72-8 C₂₁H₂₁N₅O₂ 
• 1422125-49-2 C₂₄H₂₅N₇O₄S 
• 1422125-93-6 C₂₂H₂₃N₇O 
• 1309774-09-1 1-benzyl-3-(7-bromo-1,5-naphthyridin-2-yl)urea 
• 1309774-08-0 1-(7-bromo-1,5-naphthyridin-2-yl)-3-phenylurea 
• 1422125-94-7 N-((7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl)carbamothioyl)benzamide 

Relevant articles and documents

SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as Aurora kinase inhibitors

As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7-aryl-1,5-naphthyridin-4-yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5-Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1-cyclopropyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-4-yl]urea (49), displayed IC50 values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer-related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents. Promising Aurora inhibitors: Herein we report a series of (7-aryl-1,5-naphthyridin-4-yl)ureas as a novel class of nanomolar-range Aurora kinase inhibitors. The described derivatives have good cell-penetration parameters and safety profiles, but their efficiency toward signaling pathways are insufficient to induce cell death. We also highlight their selectivity toward a panel of seven cancer-related protein kinases. Copyright

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells

A novel series of (7-aryl-1,5-naphthyridin-2-yl)ureas was discovered as dual ERK2 and Aurora B kinases inhibitors. Several analogues were active at micromolar and submicromolar range against ERK2 and Aurora B, associated with very promising antiproliferat

1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

A 1,5-naphthyridine derivative represented by Formula [1] (in which R1, R2, R3, R4 and R5 represent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L re

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.